PPARG and neoplasm: In the premenopausal cohort, across tumor receptor types (HER2‐negative, ER+, TNBC), patients with low PPARγ expression have lower survival, especially in the ER+ and TNBC cohorts where there is marginal significance; in the HER2‐negative cohort, there are minimal differences across the two groups (Figure 2b,e,h).